On the other hand, in LN229, the lack of mutation in IDH1 implies a different genetic profile and therapeutic response compared to gliomas with IDH1 mutations, where it has been observed that this gene mutation sensitizes tumor cells to various chemotherapeutic agents [52]. The gene discussed is IDH1; the disease is central nervous system cancer.